Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers

Joseph F. Poduslo, Geoffry L. Curran

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Our previous investigations have demonstrated increased permeability across the blood-nerve barrier of human plasma albumin after glycation with d-glucose [J.F. Poduslo and G.L. Curran, Proc. Natl. Acad. Sci. USA, 89 (1992) 2218-2222]. In the present investigation, the generality of this observation was evaluated by measuring the permeability coefficient-surface area product (PS) after correction for the residual plasma volume (Vp) across the blood-nerve barrier (BNB), as well as the blood-brain barrier (BBB), for nerve growth factor (NGF) and human IgG after in vitro glycation with d-glucose using an i.v. bolus injection technique in the cannulated brachial vein and artery of normal adult rats. Glycated proteins (gNGF and gIgG) had significantly decreased circulating plasma half-lives compared to the non-glycated proteins. The PS across the BNB obtained for gNGF was significantly increased compared to NGF with a 2.0-fold increase observed after 8 weeks of glycation and a 5.1-fold increase at 21 weeks of glycation. The Vp measurement for NGF and gNGF across the BNB was not significantly different at 8 weeks of glycation but was 1.3-fold greater at 21 weeks of glycation. The PS across the BBB for gNGF was about 2-fold greater than NGF with a glycation time of 8 weeks and 3.2-3.6-fold greater with a glycation time of 21 weeks for six different brain regions. No changes were observed in the Vp for any of the brain regions for gNGF compared to NGF. The PS across the BNB for gIgG compared to IgG was significantly greater with a 4.1-fold relative increase and no significant difference in the Vp values. The PS across the BBB for gIgG ranged from a 2.8-fold increase for the thalamus to a 5.1-fold increase for the caudate putamen when compared to IgG. Again no significant differences were observed for the Vp values. These data demonstrate that glycation can enhance the permeability across the BNB and BBB of proteins with widely varying molecular weight and function. Since the glycation of NGF does not appear to affect its neurotrophic activity, systemic deliver of gNGF might be useful for treating a variety of neurodegenerative diseases. Similarly, the glycation of monoclonal immunoglobulins might be a convenient procedure for delivery of a variety of antigens into the nervous system.

Original languageEnglish (US)
Pages (from-to)157-162
Number of pages6
JournalMolecular Brain Research
Volume23
Issue number1-2
DOIs
StatePublished - 1994

Fingerprint

Blood-Nerve Barrier
Nerve Growth Factor
Blood-Brain Barrier
Blood Proteins
Permeability
Immunoglobulin G
Glucose
Proteins
Residual Volume
Brachial Artery
Plasma Volume
Putamen
Brain
Thalamus
Serum Albumin
Neurodegenerative Diseases
Nervous System
Immunoglobulins
Veins
Molecular Weight

Keywords

  • Blood-brain barrier
  • Blood-nerve barrier
  • Immunoglobulin
  • Nerve growth factor
  • Permeability coefficient-surface area product
  • Residual brain/endoneurial plasma volume

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience

Cite this

Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. / Poduslo, Joseph F.; Curran, Geoffry L.

In: Molecular Brain Research, Vol. 23, No. 1-2, 1994, p. 157-162.

Research output: Contribution to journalArticle

Poduslo, Joseph F. ; Curran, Geoffry L. / Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. In: Molecular Brain Research. 1994 ; Vol. 23, No. 1-2. pp. 157-162.
@article{90547fdc97074e4898946efd4a2909dd,
title = "Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers",
abstract = "Our previous investigations have demonstrated increased permeability across the blood-nerve barrier of human plasma albumin after glycation with d-glucose [J.F. Poduslo and G.L. Curran, Proc. Natl. Acad. Sci. USA, 89 (1992) 2218-2222]. In the present investigation, the generality of this observation was evaluated by measuring the permeability coefficient-surface area product (PS) after correction for the residual plasma volume (Vp) across the blood-nerve barrier (BNB), as well as the blood-brain barrier (BBB), for nerve growth factor (NGF) and human IgG after in vitro glycation with d-glucose using an i.v. bolus injection technique in the cannulated brachial vein and artery of normal adult rats. Glycated proteins (gNGF and gIgG) had significantly decreased circulating plasma half-lives compared to the non-glycated proteins. The PS across the BNB obtained for gNGF was significantly increased compared to NGF with a 2.0-fold increase observed after 8 weeks of glycation and a 5.1-fold increase at 21 weeks of glycation. The Vp measurement for NGF and gNGF across the BNB was not significantly different at 8 weeks of glycation but was 1.3-fold greater at 21 weeks of glycation. The PS across the BBB for gNGF was about 2-fold greater than NGF with a glycation time of 8 weeks and 3.2-3.6-fold greater with a glycation time of 21 weeks for six different brain regions. No changes were observed in the Vp for any of the brain regions for gNGF compared to NGF. The PS across the BNB for gIgG compared to IgG was significantly greater with a 4.1-fold relative increase and no significant difference in the Vp values. The PS across the BBB for gIgG ranged from a 2.8-fold increase for the thalamus to a 5.1-fold increase for the caudate putamen when compared to IgG. Again no significant differences were observed for the Vp values. These data demonstrate that glycation can enhance the permeability across the BNB and BBB of proteins with widely varying molecular weight and function. Since the glycation of NGF does not appear to affect its neurotrophic activity, systemic deliver of gNGF might be useful for treating a variety of neurodegenerative diseases. Similarly, the glycation of monoclonal immunoglobulins might be a convenient procedure for delivery of a variety of antigens into the nervous system.",
keywords = "Blood-brain barrier, Blood-nerve barrier, Immunoglobulin, Nerve growth factor, Permeability coefficient-surface area product, Residual brain/endoneurial plasma volume",
author = "Poduslo, {Joseph F.} and Curran, {Geoffry L.}",
year = "1994",
doi = "10.1016/0169-328X(94)90222-4",
language = "English (US)",
volume = "23",
pages = "157--162",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers

AU - Poduslo, Joseph F.

AU - Curran, Geoffry L.

PY - 1994

Y1 - 1994

N2 - Our previous investigations have demonstrated increased permeability across the blood-nerve barrier of human plasma albumin after glycation with d-glucose [J.F. Poduslo and G.L. Curran, Proc. Natl. Acad. Sci. USA, 89 (1992) 2218-2222]. In the present investigation, the generality of this observation was evaluated by measuring the permeability coefficient-surface area product (PS) after correction for the residual plasma volume (Vp) across the blood-nerve barrier (BNB), as well as the blood-brain barrier (BBB), for nerve growth factor (NGF) and human IgG after in vitro glycation with d-glucose using an i.v. bolus injection technique in the cannulated brachial vein and artery of normal adult rats. Glycated proteins (gNGF and gIgG) had significantly decreased circulating plasma half-lives compared to the non-glycated proteins. The PS across the BNB obtained for gNGF was significantly increased compared to NGF with a 2.0-fold increase observed after 8 weeks of glycation and a 5.1-fold increase at 21 weeks of glycation. The Vp measurement for NGF and gNGF across the BNB was not significantly different at 8 weeks of glycation but was 1.3-fold greater at 21 weeks of glycation. The PS across the BBB for gNGF was about 2-fold greater than NGF with a glycation time of 8 weeks and 3.2-3.6-fold greater with a glycation time of 21 weeks for six different brain regions. No changes were observed in the Vp for any of the brain regions for gNGF compared to NGF. The PS across the BNB for gIgG compared to IgG was significantly greater with a 4.1-fold relative increase and no significant difference in the Vp values. The PS across the BBB for gIgG ranged from a 2.8-fold increase for the thalamus to a 5.1-fold increase for the caudate putamen when compared to IgG. Again no significant differences were observed for the Vp values. These data demonstrate that glycation can enhance the permeability across the BNB and BBB of proteins with widely varying molecular weight and function. Since the glycation of NGF does not appear to affect its neurotrophic activity, systemic deliver of gNGF might be useful for treating a variety of neurodegenerative diseases. Similarly, the glycation of monoclonal immunoglobulins might be a convenient procedure for delivery of a variety of antigens into the nervous system.

AB - Our previous investigations have demonstrated increased permeability across the blood-nerve barrier of human plasma albumin after glycation with d-glucose [J.F. Poduslo and G.L. Curran, Proc. Natl. Acad. Sci. USA, 89 (1992) 2218-2222]. In the present investigation, the generality of this observation was evaluated by measuring the permeability coefficient-surface area product (PS) after correction for the residual plasma volume (Vp) across the blood-nerve barrier (BNB), as well as the blood-brain barrier (BBB), for nerve growth factor (NGF) and human IgG after in vitro glycation with d-glucose using an i.v. bolus injection technique in the cannulated brachial vein and artery of normal adult rats. Glycated proteins (gNGF and gIgG) had significantly decreased circulating plasma half-lives compared to the non-glycated proteins. The PS across the BNB obtained for gNGF was significantly increased compared to NGF with a 2.0-fold increase observed after 8 weeks of glycation and a 5.1-fold increase at 21 weeks of glycation. The Vp measurement for NGF and gNGF across the BNB was not significantly different at 8 weeks of glycation but was 1.3-fold greater at 21 weeks of glycation. The PS across the BBB for gNGF was about 2-fold greater than NGF with a glycation time of 8 weeks and 3.2-3.6-fold greater with a glycation time of 21 weeks for six different brain regions. No changes were observed in the Vp for any of the brain regions for gNGF compared to NGF. The PS across the BNB for gIgG compared to IgG was significantly greater with a 4.1-fold relative increase and no significant difference in the Vp values. The PS across the BBB for gIgG ranged from a 2.8-fold increase for the thalamus to a 5.1-fold increase for the caudate putamen when compared to IgG. Again no significant differences were observed for the Vp values. These data demonstrate that glycation can enhance the permeability across the BNB and BBB of proteins with widely varying molecular weight and function. Since the glycation of NGF does not appear to affect its neurotrophic activity, systemic deliver of gNGF might be useful for treating a variety of neurodegenerative diseases. Similarly, the glycation of monoclonal immunoglobulins might be a convenient procedure for delivery of a variety of antigens into the nervous system.

KW - Blood-brain barrier

KW - Blood-nerve barrier

KW - Immunoglobulin

KW - Nerve growth factor

KW - Permeability coefficient-surface area product

KW - Residual brain/endoneurial plasma volume

UR - http://www.scopus.com/inward/record.url?scp=0028273935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028273935&partnerID=8YFLogxK

U2 - 10.1016/0169-328X(94)90222-4

DO - 10.1016/0169-328X(94)90222-4

M3 - Article

C2 - 8028478

AN - SCOPUS:0028273935

VL - 23

SP - 157

EP - 162

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -